| |
Group A Pre 2000 (n = 293)
|
Group B 2000–2007 (n = 160)
|
Group C Post 2008 (n = 91)
|
P
|
|---|
|
Observation time (years)
|
3.52 ± 1.6
|
3.25 ± 1.7
|
3.7 ± 2.2
|
NS
|
|
Age at onset
|
36.4 ± 11.9
|
35.8 ± 13.0
|
37.6 ± 11.4
|
NS
|
|
Gender male, n (%)
|
121 (41.3)
|
74 (46.3)
|
37 (40.7)
|
0.81
|
|
HLA-B51, n (%)
|
103 (53.4)
|
47 (50.0)
|
16 (43.1)
|
0.031
a
|
|
Complete type, n (%)
|
99 (33.8)
|
37 (23.1)
|
16 (17.6)
|
0.0008
|
|
Oral ulcer, n (%)
|
291 (99.3)
|
159 (99.4)
|
88 (96.7)
|
0.079
|
|
Genital ulcer, n (%)
|
219 (74.7)
|
112 (70.0)
|
55 (60.4)
|
0.0096
|
|
Eye involvement, n (%)
|
184 (62.8)
|
85 (53.1)
|
53 (58.2)
|
0.19
|
|
Skin involvement, n (%)
|
255 (87.0)
|
137 (85.6)
|
75 (82.4)
|
0.28
|
|
GI, n (%)
|
18 (6.1)
|
19 (11.9)
|
14 (16.5)
|
0.0036
|
|
CNS, n (%)
|
20 (6.8)
|
14 (8.8)
|
3 (3.3)
|
0.46
|
|
Vascular, n (%)
|
17 (5.8)
|
15 (9.4)
|
3 (3.3)
|
0.73
|
|
Complete type fulfilling, n ISG (%)
|
99/264 (37.5)
|
37/135 (27.4)
|
16/74 (21.6)
|
0.0037
|
|
Complete type w/o GI, n (%)
|
96/275 (34.9)
|
35/141 (24.8)
|
15/77 (19.5)
|
0.0030
|
- Numbers of patients shown are different from Table 2 because 31 patients were excluded due to ambiguity of the date of phenotype expression. aNot all of the patients were typed for HLA-B51 positivity. GI gastrointestinal, CNS central nervous system, w/o without, NS not significant
